Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,552.93
(
-0.81%
)
US TECH 100
23,438.00
(
-1.19%
)
Dow Jones
45,811.01
(
-0.46%
)
Brent Oil
106.27
(
1.76%
)
Bitcoin
70,165.00
(
0.38%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 177138

Sunday, 10/25/2015 7:36:24 PM

Sunday, October 25, 2015 7:36:24 PM

Post# of 257262
Barron’s piece on GSK cites NVS and ABT as comparators for valuation purposes, which is odd insofar as NVS and ABT don’t have much in common with each other:

http://www.barrons.com/articles/a-shot-in-the-arm-for-glaxosmithkline-1445665382

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today